On June 11, 2020, Hu, Yonghan; Wu, Dongdong; Peng, Wei; Lu, Liang; Li, Xin; Zhang, Xiuchun; Wang, Ruzhi; Zhu, Sheng; Huang, Bin; Liu, Tao; Zhu, Jinlian; Wu, Yuchuan published a patent.Recommanded Product: 1198284-94-4 The title of the patent was Heterocyclic compound, application and pharmaceutical composition and application. And the patent contained the following:
The invention disclosed a kind of heterocyclic compound, its preparation method and application. The claimed compound is shown in structure I (R1 = H, F, difluoromethyl, OMe, cyclopropyl, etc.; Y1 = N or CH; Y2 = N, CH, C(F), etc.; R9 = H, Me, or difluoromethyl; X1 = N, CH, C(OH), etc.; s,t = 0 or 1; X3 = N; X2 = CH2, or C(O); X4 = hetero atom containing fragment forming heterocycle; X6 = C(O), or CH2. CHR; R = C1-4 alkyl; X5 = N or CH; R6 = H, halo, cyclopropyl, etc.; R7 = H or halo; R8 = (un)substituted C1-4 alkyl, halo, cyclopropyl, oe H). The claimed compound is prepared via multiple steps (procedure given). The prepared compound can be used as RET kinase inhibitor for treating and preventing diseases mediated by abnormal expression of RET such as cancers (papillary thyroid carcinoma, medullary thyroid carcinoma, pheochromocytoma, pancreatic ductal adenocarcinoma, multiple endocrine tumors (also for example MEN2A or MEN2B), breast cancer (also for example metastatic breast cancer), testicular cancer, small cell lung cancer, Non-small cell lung cancer, chronic bone marrow mononuclear leukemia, colon cancer, rectal cancer, ovarian cancer, or salivary adenocarcinoma). The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Recommanded Product: 1198284-94-4
The Article related to heterocyclic compound preparation ret kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 1198284-94-4
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics